Author: Jhaveri, Ravi
Title: The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World Cord-id: wds48jq5 Document date: 2021_3_23
ID: wds48jq5
Snippet: The approval of the COVID-19 mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization and several other vaccines likely to follow. These vaccines all utilize relatively new vaccine production platforms to produce the SARS-CoV2 Spike protein. This review discusses how these platforms work, what advantages they offer and the gaps that remain in public health efforts to control the COVID-19 pandemic.
Document: The approval of the COVID-19 mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization and several other vaccines likely to follow. These vaccines all utilize relatively new vaccine production platforms to produce the SARS-CoV2 Spike protein. This review discusses how these platforms work, what advantages they offer and the gaps that remain in public health efforts to control the COVID-19 pandemic.
Search related documents:
Co phrase search for related documents- active vaccine and low cost production: 1
- active vaccine and low efficacy: 1, 2, 3, 4
- active vaccine and low production: 1
- active vaccine and low production cost: 1
- additional vaccine and adenovirus vector: 1
- adenovirus vector and adjuvant antigen: 1
- adenovirus vector and low cost production: 1
- adenovirus vector and low efficacy: 1, 2
- adenovirus vector and low production: 1, 2
- adenovirus vector and low production cost: 1
- adjuvant antigen and low dose receive: 1
Co phrase search for related documents, hyperlinks ordered by date